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ABSTRACT 
We investigated impacts of increased generic drug use on spontaneous adverse event reports (SAERs), 
because SAERs have been a major source of data for drug safety assessment at the post-market stage. 
Reporting proportion of SAERs for the generic drugs was consistently and significantly lower than that for 
the original branded drugs. The reporting proportion targeting for 55 APIs, which had the longest follow-
up period after generic drug marketed, gradually decreased for the original branded drugs and increased for 
the generic drugs. However, these transitions did not parallel the changes in market share over the same 
period. These results suggest that the reporting proportion of SAERs for generic drugs may not keep pace 
with growth in market share. When generic drugs account for the majority of market share, utilization of 
multiple sources of information and data, in addition to SAERs, maybe a key to assuring drug safety at the 
post-market stage. 
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INTRODUCTION 
Medical care costs in Japan have risen sharply in recent years due to a number of factors, including a 
rapidly aging society and the availability of advanced medical therapies. Indeed, the medical cost in Japan 
exceeded 40 trillion yen in the fiscal year (FY; April to March of the following year) 2015.1 A similar 
situation has also been reported in the US.2 To control medical care costs, the Ministry of Health, Labour 
and Welfare (MHLW) has announced a new initiative entitled “Roadmap to further promotion of generic 
drug utilization” in April 2013.3 Since then, the use of generic drugs in Japan has gradually increased year 
on year.4 In June 2015, a new target to increase the market share of generic drugs to over 80% by the period 
of 2018-2020 was set by the cabinet. Utilization of generic drugs has been more advanced in foreign 
countries, because its market share was reported as more than 75% in Germany, UK and US in 2014-2016, 
but 56.2 % in Japan in 2015.4  
Regulatory safety action at the post-market stage is primarily based on spontaneous adverse event reports 
(SAERs), which are mainly submitted by the pharmaceutical industry. For example, safety-related drug 
label changes were a result of SAERs in more than 50% of cases in the US 5, 6  and approximately 83% of 
cases in Japan.7 In terms of the regulation on SAERs in Japan, same requirement is imposed for the 
Marketing Authorisation Holders (MAHs) of original branded and generic drugs. 
Thus, it is important to investigate how changes in drug market share might impact on the reporting of 
spontaneous adverse events by the pharmaceutical industry. If SAERs were significantly affected by 
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increased market share of generic drugs, its influence on post-market safety assessment should be 
considered. We compared a ratio of SAERs for generic drugs with that for original branded drugs and 
examined the factors affecting this ratio. We also discuss an efficient assessment of post-market drug safety 
in the era of major utilization of generic drugs.  
 
RESULTS 
Of the 108 target active product ingredients (APIs), “Cardiovascular agents” were the most common, 
followed by “Miscellaneous metabolism agents” and “Central nervous system agents” (Table 1). Median 
of the year after generic marketed was 11±0.8 (6～18) (median±standard error (interquartile range)) years 
that included 55 APIs for 11 years and more, 28 APIs for less than 11 years and 6 years and more, 25 APIs 
for less than 6 years.  
“Proportion Ratio of SAERs” (see methods) was consistently and significantly lower than 1.0 in all years 
examined in this study (FY 2005-FY2015) (p<0.05: the Cochran-Mantel-Haenszel test), indicating that in 
various drug categories examined in this study, reporting proportion of SAERs for the generic drugs was 
lower than that for the original branded drugs (Figure 1). When examining effects of background factors 
on the reporting proportion, the proportion was significantly lower in the APIs whose market share of 
generic drugs for an API (FY 2015) was less than 52.1% (median share) (p<0.05: ANOVA) (Table 2). A 
tendency of less frequent reporting also correlated with fewer years after the first generic drug marketed, 
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fewer number of companies marketing generic drugs, and lower total number of employees of all companies 
marketing generic drugs for an API.    
To further understand the relationship between market share and years after generic drug marketed, we 
examined the relationship between changes in market share and reporting proportion for 55 APIs, which 
had the longest follow-up period of 11 years after generic marketed. As shown in Figure 2, market share 
gradually decreased for the original branded drugs and increased for generic drugs. For example, the share 
of 18.6% in FY2005 for the generic drugs increased to 52.8% in FY2015. Interestingly, the reporting 
proportion also gradually decreased for the original branded drugs and increased for the generic drugs, but 
these transitions did not parallel changes in market share. Consequently, the reporting proportion of the 
generic drugs did not keep pace with market share over time. For example, in FY2015, although more than 
half of the market share was for generic drugs, their reporting proportion was still 37.5% (i.e. the other 
62.5% of SAERs were for original branded drugs). 
 
DISCUSSION 
SAERs have been utilized as an important source of information for post-marketing safety measures.5-7 
Impacts of growth market share of generic drugs on SAERs in Japan have not been studied, although lower 
reporting proportion of generic antiepileptic drugs has been reported in the US.8 This study shows that the 
reporting proportion of SAERs is lower for generic drugs than for the original branded drugs marketed in 
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Japan. Because the market share obtained in this study is similar to that published by MHLW,4 our results 
reflect a common situation on the reporting proportion of SAERs in Japan. 
A gradual decrease of the ratio after FY2008 in Figure 1 may correlate with a phenomenon that losing 
the pace of the reporting proportion of the generic drugs with market share has been initiated since FY2009 
(Figure 2). This phenomenon may be due to the additional incentive to pharmacies on the insurance 
reimbursement since FY 2008 for further promoting use of generic drugs.9 Growing medical care costs 
resulting from an aging society is an issue not only in Japan but also in other developed countries.2 Although 
the promotion of generic drugs is a commonly used strategy to manage the spiraling cost of medical care, 
this presents a challenge to drug safety assurance at the post-market stage, especially after generic drug 
approval. As suggested in this study, the lower reporting proportion of generic drugs with considerable 
market share may decrease information contents for drug safety at the post-market stage. If safety 
assessment continues to be mainly based on SAERs, there may be a delay in the implementation of drug 
safety measures by a regulatory authority. As shown in Figure 2, there is a possibility that MAH of the 
original branded drugs may compensate for the lower proportion of SAERs of generic drugs. This may be 
due to less accessible for reporters to generic drug companies which have fewer resources than original 
branded drug companies (i.e., receiving fewer adverse event reports possibly due to less communications 
with physician and other medical staffs).10 In this situation, SAERs would not then reflect a real situation 
in which most drugs used in clinical practice are generics, resulting in improper categorization of generic-
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associated adverse events to the original branded drug and causing more difficult situation to evaluate a 
product-specific safety concern. It would be unrealistic to expect increased reporting of SAERs by MAHs 
of generic drugs due to their limited resources in comparison with those of original branded drugs, because 
fewer medical representatives in a generic company than an original branded company10 and the positive 
relationship between numbers of sales representatives and of safety reporting11 have been reported. Stricter 
regulation on generic drugs for having more SAERs may be one of options, but may make negative impacts 
in promoting generic drug use. To control medical care costs, recession of generic drug use resulting from 
the stricter regulation should be avoided.  
Therefore, future drug safety assessments should take account of the increasing market share of generic 
drugs when information on SAERs may be limited. Firstly, further promotion of SAERs from health care 
professionals rather than MAHs may be important, since number of SAERs from health care professionals 
is still very limited in Japan (approximately 1% of total reports).12 In addition, an independent data source 
from SAERs should be made available for drug safety assessment at the post-market stage. To this end, 
utilization of real-world data is currently being actively discussed.13-15 In Japan, the MIHARI project has 
been conducted to promote utilization of large-scale electronic health information databases for post-market 
drug safety.16 In addition to the claim data, MID-NETⓇ, which is an electronic medical records (EMRs) 
database established in cooperation with 10 medical institutions including 23 hospitals, was formally 
implemented in April 2018 in Japan.17 Drug safety assessment based on these databases could include safety 
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assessment of generic drugs and will be expected to enhance quality of drug safety assessment at post-
market stage. Recently, application of the sentinel database to assess generic drugs in terms of switching 
pattern has been reported.18 Data from patient registries and social media are also expected to be utilized in 
the regulatory process worldwide in the near future.19-21 Information available at the post-market stage will 
be changed in line with the social healthcare situation. We need to prepare in response to such changes by 
utilizing multiple source of information and data, which depends not mainly on SAERs, to assure drug 
safety at post-market stage.    
In conclusion, the results from our analysis suggest that the reporting proportion of SAERs for generic 
drugs may not keep pace with growth in market share. In response, we should consider utilizing multiple 
sources of information and data in addition to SAERs to assure drug safety at the post-market stage when 
generic drugs account for the majority of market share. Utilization of real-world data, such as EMRs, patient 
registries and social media, is a promising approach that is independent from SAERs and is expected to be 
increasingly implemented in the regulatory process. 
 
METHODS 
Data Sources 
The number of SAERs in Japan was obtained from the Japanese Adverse Drug Event Report database 
(JADER),22 which is available on the website of Pharmaceuticals and Medical Devices Agency (PMDA). 
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JADER consists of the reports from MAHs and health care professionals. The reports from MAH for the 
period from FY 2005 to FY 2015 were extracted from JADER for analysis to focus on the effects of industry 
factors on SAERs.  
The national wide estimated number of patients was obtained from commercially available Japanese 
claims database (JMDC Inc.(Tokyo, Japan))23 for the period from FY 2005 to FY 2015. This database 
includes patient’s characteristics (age and sex), prescribed or dispensed medications, and procedures and 
diagnoses for approximately 5.6 million patients from multiple healthcare insurance associations and is 
widely used for pharmacoepidmeiological researches.24  
 
Selection of Drugs 
To investigate the trend of SAERs, we focused the top 500 products on sales in FY 2015 based on a 
survey (Japan Pharmaceutical Market) conducted by IQVIA.25 Within the top 500 products, we extracted 
144 products corresponding to 114 APIs (small molecules) for which the generic drug was approved over 
a period between FY 2008 and FY 2012 for allowing at least three years before and after generic drug 
approval. This strategy ensured a sufficient number of SAERs during follow-up period before and after 
generic drug approval were available for analysis. Of 114 APIs, 6 APIs whose original branded drug was 
not marketed26 (i.e. acetaminophen, ketoprofen, aspirin, mecobalamin, magnesium oxide, and calcium 
polystyrene sulfonate) were excluded from analysis. Therefore, 108 APIs were used for analysis. An 
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approval status of each drug was confirmed based on the information published on the website of the 
Federation of Pharmaceutical Manufacturers’ Associations of JAPAN.27 For original branded drugs, data 
for the dosage form approved for the generic drugs was only used for analyasis. For example, epinastine 
hydrochloride oral formulation was included in the analysis, but data for the ophthalmic solution was 
excluded because no generic drugs for the ophthalmic solution had been approved. 
 
Analysis 
For classification of drugs by efficacy, we used the division 87 (drugs and related commodities) of Japan 
Standard Commodity Classification28 established by the Ministry of Internal Affairs and Communications. 
If multiple categories were counted for an API, each category was included as a separate case in the analysis. 
The median and interquartile range of years after the first generic drug marketed per each API were 
calculated. In order to compare the reporting proportion of SAERs, for every API, the number of SAERs 
in JADER per FY were calculated for original branded drugs and for generic drugs over a period from 
FY2005 to FY2015. SAERs with a proprietary name of a branded drug were only counted as reports of 
branded drugs and the others such as SAERs with a proprietary name of a generic drug or without any 
proprietary name of a drug were counted as reports of generic drugs. If more than one drug was listed in a 
SAER, only the primary drug suspected of causing the adverse reaction was included in the analysis. The 
national wide estimated numbers of patients with prescriptions of each API’s original branded drugs and 
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generic drugs per FY were calculated using the ID given by JMDC. “Proportion Ratio of SAERs” defined 
as the formula of (the number of SAERs of generic drugs / the national wide estimated number of patients 
using generic drugs) / (the number of SAERs of original branded drugs / the national wide estimated number 
of patients using original branded drugs) was used for comparisons among APIs by employing the Cochran-
Mantel-Haenszel test.29 
In addition, we investigated the relationship between market share and reporting proportion about 55 
APIs with the longest follow-up period of 11 years after generic marketed. Market share and reporting 
proportion were calculated for original branded drugs and generic drugs of an API over a period from 
FY2005 to FY2015. The market share of original branded drugs was obtained from the formula of (the 
national wide estimated number of patients using original branded drugs) / (the national wide estimated 
number of patients using original branded drugs + the national wide estimated number of patients using 
generic drugs). Reporting proportion of original branded drugs was obtained from the formula of (the 
number of SAERs of original branded drugs) / (the number of SAERs of original branded drugs + the 
number of SAERs of generic drugs).  Analysis for the generic drugs was performed in the same way.  
The number of MAHs for each API was calculated based on the information of package inserts, which 
were available on the PMDA website. The number of employees in the relevant MAH for each API was 
defined by the information of MAH's official website or job sites. The number of employees was 
unavailable for 5 MAHs, which were excluded from the analysis. 
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STUDY HIGHLIGHTS 
What is the current knowledge on the topic? 
The use of generic drugs in Japan has gradually increased year on year. Safety measures at the post-
market stage is primarily based on spontaneous adverse event reports (SAERs). 
 
What question did this study address? 
Impacts of growth market share of generic drugs on SAERs. 
 
What does this study add to our knowledge? 
Reporting proportion of SAERs for the generic drugs was consistently and significantly lower than that 
for the original branded drugs.  
The reporting proportion of SAERs for generic drugs did not keep pace with growth in market share. 
 
How might this change clinical pharmacology or translational science? 
Multiple sources of information and data, in addition to SAERs, should be used to assure drug safety at 
the post-market stage when generic drugs account for the majority of market share. 
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FIGURE LEGENDS 
 
Table1 
Drug category for the targeted APIs in this study 
If multiple categories were counted for an API, each category was included as a separate case in the analysis. 
 
APIs, active product ingredients 
 
Fig 1 
Trends of “Proportion Ratio of SAERs”  
“Proportion Ratio of SAERs” was consistently and significantly lower than 1.0 in all years examined in 
this study (FY 2005-FY2015) (p<0.05), indicating that reporting proportion of SAERs for the generic drugs 
was lower than that for the original branded drugs. 
 
SAERs, spontaneous adverse event reports 
 
Table 2 
Effects of background factors on the reporting proportion  
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The proportion ratio of SAERs was significantly lower in the APIs when the market share of generic drugs 
in FY 2015 was less than 52.1% (median share) (p<0.05: ANOVA). A similar trend was observed for three 
other background factors, although these were not statistically significant. 
 
SAERs, spontaneous adverse event reports 
APIs, active product ingredients 
 
Fig 2 
Market share and spontaneous adverse event reporting proportion.  
Comparison was made between original branded drugs and generic drugs for 55 APIs, which had the longest 
follow-up period of 11 years after generic drug marketed. The reporting proportion gradually decreased for 
the original branded drugs and increased for the generic drugs. However, these transitions did not parallel 
changes in market share. Consequently, the reporting proportion for generic drugs did not keep pace with 
the growth in market share. 
 
APIs, active product ingredients  
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Table 1 Drug category for the targeted APIs in this study 
drug category n(%) 
Cardiovascular agents 27(23.3%) 
Miscellaneous metabolism agents 15(12.9%) 
Central nervous system agents 13(11.2%) 
Digestive organ agents 11(9.48%) 
Antibiotics 10(8.62%) 
Antineoplastics 8(6.90%) 
Epidermides 7(6.03%) 
Allergic agents 6(5.17%) 
Sensory organ agents 4(3.45%) 
Respiratory organ agents 4(3.45%) 
Blood and body fluid agents 4(3.45%) 
Vitamins 3(2.59%) 
Intracorporeal diagnostic agents 2(1.72%) 
Urogenital and anal organ agents 1(0.86%) 
Nutrients, tonics 1(0.86%) 
total 116 
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Figure 1 
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Table 2 Effects of background factors on the reporting proportion 
background factor median 
(interquartile 
range) 
 proportion ratio of 
SAERs 
year after the first generic 
drugs marketed for an API  
11(6～18) ≧11(55) 0.47 
  ＜11(53) 0.34 
    
number of companies 
marketing generic drugs 
for an API 
13 
(8～20) 
≧13(55) 0.47 
  ＜13(53) 0.35 
    
the total number of 
employees of all 
companies marketing  
generic drugs for an API 
14994 
(8241～20681) 
≧14994(54) 0.50 
  ＜14994(54) 0.31 
    
market share of generic 
drugs for an API (FY 
2015) 
52.1% 
(36.3%～62.0%) 
≧52.1%(54) 0.41 
  ＜52.1%(54) 0.35 
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Figure 2 
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